Display options
Cite
Babaei F, Ahmadi SA, Abiri R, et al. The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients. Iran J Public Health. 2014;43(4):453-9
Babaei, F., Ahmadi, S. A., Abiri, R., Rezaei, F., Naseri, M., Mahmoudi, M., Nategh, R., & Mokhtari Azad, T. (2014). The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients. Iranian journal of public health, 43(4), 453-9.
Babaei, Farhad, et al. "The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients." Iranian journal of public health vol. 43,4 (2014): 453-9.
Babaei F, Ahmadi SA, Abiri R, Rezaei F, Naseri M, Mahmoudi M, Nategh R, Mokhtari Azad T. The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients. Iran J Public Health. 2014 Apr;43(4):453-9. PMID: 26005655; PMCID: PMC4433726.
Copy Download .nbib Format: NLM
Share it on

Iran J Public Health. 2014 Apr;43(4):453-9.

The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients.

Iranian journal of public health

Farhad Babaei, Seyed Ali Ahmadi, Ramin Abiri, Farhad Rezaei, Maryam Naseri, Mahmoud Mahmoudi, Rakhshande Nategh, Talat Mokhtari Azad

Affiliations

  1. 1. Dept. of Virology, School of Public Health, Tehran University of Medical Sciences , Tehran, Iran.
  2. 2. School of Medicine, Tehran University of Medical Sciences , Tehran, Iran.
  3. 3. Dept. of Microbiology, School of Medicine, Kermanshah University of Medical Sciences , Kermanshah, Iran.
  4. 4. Dept. of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences , Tehran, Iran.

PMID: 26005655 PMCID: PMC4433726

Abstract

BACKGROUND: The TP53 gene is one of the most frequently mutated genes amongst human malignancies, particularly TP53 codon 72 polymorphism. Furthermore, an association between the TP53 codon 72 variants and prostate cancer has been reported in several studies. Although some studies have indicated an association between the TP53 Arg/Arg variant and an increased risk for prostate cancer, other studies have shown a positive correlation between the TP53 Pro/Pro genotype instead. Therefore, to clarify if this polymorphism is associated with an increased risk of prostate cancer in Iranian men, we conducted a case-control study of 40 sporadic prostate cancer patients and 80 benign prostate hyperplasia cases.

METHODS: The TP53 codon 72 was genotyped using an allele specific PCR.

RESULTS: A significant association between the TP53 codon 72 genotype and prostate cancer risk was found (OR = 6.8, 95% CI = [1.8-25.1], P = 0.005). However, the results of this study did not support an association between age, the Gleason score nor TP53 genotype at codon 72 in prostate cancer patients.

CONCLUSIONS: TP53 codon 72 polymorphism may have a great impact in the development of prostate cancer.

Keywords: Benign prostate hyperplasia; Sporadic prostate cancer; TP53 codon 72 polymorphism

References

  1. Nature. 1998 May 21;393(6682):229-34 - PubMed
  2. Clin Cancer Res. 2010 Nov 1;16(21):5244-51 - PubMed
  3. Breast Cancer Res. 2007;9(3):R34 - PubMed
  4. J Cell Biochem. 2006 Feb 15;97(3):433-47 - PubMed
  5. Nature. 1991 Jun 6;351(6326):453-6 - PubMed
  6. Cancer Genet Cytogenet. 2010 Oct 15;202(2):76-81 - PubMed
  7. Mol Cell Biol. 1999 Feb;19(2):1092-100 - PubMed
  8. Can J Urol. 2003 Aug;10(4):1924-33 - PubMed
  9. Int J Cancer. 2004 Apr 10;109(3):348-52 - PubMed
  10. Nature. 1992 Jul 2;358(6381):15-6 - PubMed
  11. Nat Genet. 2003 Mar;33(3):357-65 - PubMed
  12. J Natl Cancer Inst. 1993 Oct 20;85(20):1657-69 - PubMed
  13. Carcinogenesis. 2008 Jun;29(6):1192-6 - PubMed
  14. Infect Agent Cancer. 2011 Aug 15;6:13 - PubMed
  15. Genes Chromosomes Cancer. 2007 Mar;46(3):239-47 - PubMed
  16. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2217-24 - PubMed
  17. Science. 1991 Jul 5;253(5015):49-53 - PubMed
  18. Oncogene. 2006 Mar 13;25(11):1602-11 - PubMed
  19. Biotechniques. 1999 Feb;26(2):198-200 - PubMed
  20. PLoS Pathog. 2006 Mar;2(3):e25 - PubMed
  21. Br J Cancer. 2000 Feb;82(3):718-25 - PubMed
  22. Mol Carcinog. 2008 Feb;47(2):100-4 - PubMed
  23. Prostate. 2001 Dec 1;49(4):263-6 - PubMed
  24. J Biomed Sci. 2003 Jul-Aug;10(4):430-5 - PubMed
  25. Lung Cancer. 2007 May;56(2):145-51 - PubMed
  26. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  27. J Med Virol. 2012 Sep;84(9):1423-7 - PubMed
  28. Nat Genet. 2002 Dec;32(4):581-3 - PubMed
  29. Cancer Lett. 2002 Sep 26;183(2):123-30 - PubMed
  30. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  31. Nat Genet. 2006 Oct;38(10):1133-41 - PubMed
  32. Urol Int. 2004;73(1):41-6 - PubMed
  33. Cancer Lett. 2004 Jul 16;210(2):151-7 - PubMed
  34. Cold Spring Harb Symp Quant Biol. 1991;56:219-25 - PubMed
  35. Virus Res. 2012 Feb;163(2):644-9 - PubMed
  36. Arch Med Res. 2011 Feb;42(2):122-7 - PubMed

Publication Types